nach oben

Erschienen in:

01.03.2016 | Original Paper

Does PGC1α/FNDC5/BDNF Elicit the Beneficial Effects of Exercise on Neurodegenerative Disorders?

verfasst von: Mohammad Jodeiri Farshbaf, Kamran Ghaedi, Timothy L. Megraw, Jennifer Curtiss, Mahsa Shirani Faradonbeh, Pooneh Vaziri, Mohammad Hossein Nasr-Esfahani

Erschienen in: NeuroMolecular Medicine | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Neurodegenerative disorders such as Alzheimer’s, Parkinson’s and Huntington’s diseases have high prevalence among the elderly. Many strategies have been established to alleviate the symptoms experienced by affected individuals. Recent studies have shown that exercise helps patients with neurological disorders to regain lost physical abilities. PGC1α/FNDC5/BDNF has emerged recently as a critical pathway for neuroprotection. PGC1α is a highly conserved co-activator of transcription factors that preserves and protects neurons against destruction. PGC1α regulates FNDC5 and its processed and secreted peptide Irisin, which has been proposed to play a critical role in energy expenditure and to promote neural differentiation of mouse embryonic stem cells. FNDC5 may also increase the expression of the neurotrophic factor BDNF, a neuroprotective agent, in the hippocampus. BDNF is secreted from hippocampus, amygdala, cerebral cortex and hypothalamus neurons and initiates intracellular signaling pathways through TrkB receptors. These pathways have positive feedback on CREB activities and lead to enhancement in PGC1α expression in neurons. Therefore, FNDC5 could behave as a key regulator in neuronal survival and development. This review presents recent findings on the PGC1α/FNDC5/BDNF pathway and its role in neuroprotection, and discusses the controversial promise of irisin as a mediator of the positive benefits of exercise.

Ahlskog, J. E. (2011). Cheaper, simpler, and better: Tips for treating seniors with Parkinson disease. Mayo Clinic Proceedings, 86, 1211–1216.PubMedCentralPubMedCrossRef

Albrecht, E., Norheim, F., Thiede, B., Holen, T., Ohashi, T., Schering, L., et al. (2015). Irisin—A myth rather than an exercise-inducible myokine. Scientific reports, 5, 8889.PubMedCentralPubMedCrossRef

Amadoro, G., Corsetti, V., Florenzano, F., Atlante, A., Bobba, A., Nicolin, V., et al. (2014). Morphological and bioenergetic demands underlying the mitophagy in post-mitotic neurons: the pink-parkin pathway. Front Aging Neurosci, 6, 18.PubMedCentralPubMedCrossRef

Andreyev, A. Y., Kushnareva, Y. E., Murphy, A. N., & Starkov, A. A. (2015). Mitochondrial ROS metabolism: 10 years later. Biochemistry (Mosc), 80, 517–531.CrossRef

Antonenkov, V. D., Grunau, S., Ohlmeier, S., & Hiltunen, J. K. (2010). Peroxisomes are oxidative organelles. Antioxidants and Redox Signaling, 13, 525–537.PubMedCrossRef

Ayala, A., Muñoz, M. F., & Argüelles, S. (2014). Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxidative Medicine and Cellular Longevity, 2014, 360438.PubMedCentralPubMedCrossRef

Aydin, S., Kuloglu, T., Eren, M. N., Celik, A., Yilmaz, M., Kalayci, M., et al. (2014). Cardiac, skeletal muscle and serum irisin responses to with or without water exercise in young and old male rats: Cardiac muscle produces more irisin than skeletal muscle. Peptides, 52, 68–73.PubMedCrossRef

Baes, M., & Aubourg, P. (2009). Peroxisomes, myelination, and axonal integrity in the CNS. Neuroscientist, 15, 367–379.PubMedCrossRef

Baes, M., & Van Veldhoven, P. P. (2006). Generalised and conditional inactivation of Pex genes in mice. Biochimica et Biophysica Acta, 1763, 1785–1793.PubMedCrossRef

Baines, C. P. (2010). Role of the mitochondrion in programmed necrosis. Frontiers in Physiology, 1, 156.PubMedCentralPubMedCrossRef

Balaban, R. S., Nemoto, S., & Finkel, T. (2005). Mitochondria, oxidants, and aging. Cell, 120, 483–495.PubMedCrossRef

Bennett, S. A., Valenzuela, N., Xu, H., Franko, B., Fai, S., & Figeys, D. (2013). Using neurolipidomics to identify phospholipid mediators of synaptic (dys)function in Alzheimer’s Disease. Frontiers in Physiology, 4, 168.PubMedCentralPubMedCrossRef

Binder, D. K., & Scharfman, H. E. (2004). Brain-derived neurotrophic factor. Growth Factors, 22, 123–131.PubMedCentralPubMedCrossRef

Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., Jackson-Lewis, V.R. (2015). Oxidative stress and Parkinson’s disease. Front Neuroanat, 9, 91.PubMedCentralPubMed

Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., et al. (2012). A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature, 481, 463–468.PubMedCentralPubMedCrossRef

Bordt, E.A.,& Polster, B.M. (2014). NADPH oxidase- and mitochondria-derived reactive oxygen species in proinflammatory microglial activation: a bipartisan affair? Free Radic Biol Med, 76, 34–46.PubMedCrossRef

Braverman, N. E., & Moser, A. B. (2012). Functions of plasmalogen lipids in health and disease. Biochimica et Biophysica Acta, 1822, 1442–1452.PubMedCrossRef

Calon, F., Lim, G. P., Yang, F., Morihara, T., Teter, B., Ubeda, O., et al. (2004). Docosahexaenoic acid protects from dendritic pathology in an Alzheimer’s disease mouse model. Neuron, 43, 633–645.PubMedCentralPubMedCrossRef

Carlezon, W. A., Duman, R. S., & Nestler, E. J. (2005). The many faces of CREB. Trends in Neurosciences, 28, 436–445.PubMedCrossRef

Castillo-Quan, J. I. (2011). Parkin’ control: Regulation of PGC-1α through PARIS in Parkinson’s disease. Disease Models and Mechanisms, 4, 427–429.PubMedCentralPubMedCrossRef

Chapman, P. F., White, G. L., Jones, M. W., Cooper-Blacketer, D., Marshall, V. J., Irizarry, M., et al. (1999). Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nature Neuroscience, 2, 271–276.PubMedCrossRef

Chaturvedi, R. K., & Beal, M. F. (2013). Mitochondrial diseases of the brain. Free Radical Biology and Medicine, 63, 1–29.PubMedCrossRef

Chen, H., McCaffery, J. M., & Chan, D. C. (2007). Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell, 130, 548–562.PubMedCrossRef

Chen, Z. Y., Patel, P. D., Sant, G., Meng, C. X., Teng, K. K., Hempstead, B. L., & Lee, F. S. (2004). Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. Journal of Neuroscience, 24, 4401–4411.PubMedCrossRef

Ciccone, S., Maiani, E., Bellusci, G., Diederich, M., & Gonfloni, S. (2013). Parkinson’s disease: A complex interplay of mitochondrial DNA alterations and oxidative stress. International Journal of Molecular Sciences, 14, 2388–2409.PubMedCentralPubMedCrossRef

Clark, J., Reddy, S., Zheng, K., Betensky, R. A., & Simon, D. K. (2011). Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson’s disease. BMC Medical Genetics, 12, 69.PubMedCentralPubMedCrossRef

Connolly, A. M., Chez, M., Streif, E. M., Keeling, R. M., Golumbek, P. T., Kwon, J. M., et al. (2006). Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau–Kleffner syndrome, and epilepsy. Biological Psychiatry, 59, 354–363.PubMedCrossRef

Conquer, J. A., Tierney, M. C., Zecevic, J., Bettger, W. J., & Fisher, R. H. (2000). Fatty acid analysis of blood plasma of patients with Alzheimer’s disease, other types of dementia, and cognitive impairment. Lipids, 35, 1305–1312.PubMedCrossRef

Corona, J. C., & Duchen, M. R. (2015). PPARγ and PGC-1α as therapeutic targets in Parkinson’s. Neurochemical Research, 40, 308–316.PubMedCentralPubMedCrossRef

Cotman, C. W., Berchtold, N. C., & Christie, L. A. (2007). Exercise builds brain health: Key roles of growth factor cascades and inflammation. Trends in Neurosciences, 30, 464–472.PubMedCrossRef

Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., & Krainc, D. (2006). Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell, 127, 59–69.PubMedCrossRef

del Río, L. A., Corpas, F. J., Sandalio, L. M., Palma, J. M., Gómez, M., & Barroso, J. B. (2002). Reactive oxygen species, antioxidant systems and nitric oxide in peroxisomes. Journal of Experimental Botany, 53, 1255–1272.PubMedCrossRef

Desai, N. S., Rutherford, L. C., & Turrigiano, G. G. (1999). BDNF regulates the intrinsic excitability of cortical neurons. Learning and Memory, 6, 284–291.PubMedCentralPubMed

Dun, S. L., Lyu, R. M., Chen, Y. H., Chang, J. K., Luo, J. J., & Dun, N. J. (2013). Irisin-immunoreactivity in neural and non-neural cells of the rodent. Neuroscience, 240, 155–162.PubMedCentralPubMedCrossRef

Dwivedi, Y. (2009). Brain-derived neurotrophic factor: Role in depression and suicide. Neuropsychiatric Disease and Treatment, 5, 433–449.PubMedCentralPubMedCrossRef

Edmondson, D. E. (2014). Hydrogen peroxide produced by mitochondrial monoamine oxidase catalysis: biological implications. Current Pharmaceutical Design, 20, 155–160.PubMedCrossRef

Eichner, L. J., & Giguère, V. (2011). Estrogen related receptors (ERRs): A new dawn in transcriptional control of mitochondrial gene networks. Mitochondrion, 11, 544–552.PubMedCrossRef

Erickson, H. P. (2013). Irisin and FNDC5 in retrospect: An exercise hormone or a transmembrane receptor? Adipocyte, 2, 289–293.PubMedCentralPubMedCrossRef

Evans, R. M. (2005). The nuclear receptor superfamily: A rosetta stone for physiology. Molecular Endocrinology, 19, 1429–1438.PubMedCrossRef

Exner, N., Lutz, A.K., Haass, C., Winklhofer, K.F. (2012). Mitochondrial dysfunction in Parkinson’s disease: molecular mechanisms and pathophysiological consequences. EMBO J, 31(14), 3038–3062.PubMedCentralPubMedCrossRef

Farrar, G. J., Chadderton, N., Kenna, P. F., & Millington-Ward, S. (2013). Mitochondrial disorders: Aetiologies, models systems, and candidate therapies. Trends in Genetics, 29, 488–497.PubMedCrossRef

Ferreiro, E., Baldeiras, I., Ferreira, I. L., Costa, R. O., Rego, A. C., Pereira, C. F., & Oliveira, C. R. (2012). Mitochondrial- and endoplasmic reticulum-associated oxidative stress in Alzheimer’s disease: From pathogenesis to biomarkers. International Journal of Cell Biology, 2012, 735206.PubMedCentralPubMedCrossRef

Ferrer-Martínez, A., Ruiz-Lozano, P., & Chien, K. R. (2002). Mouse PeP: A novel peroxisomal protein linked to myoblast differentiation and development. Developmental Dynamics, 224, 154–167.PubMedCrossRef

Fiore, M., Chaldakov, G. N., & Aloe, L. (2009). Nerve growth factor as a signaling molecule for nerve cells and also for the neuroendocrine-immune systems. Reviews in the Neurosciences, 20, 133–145.PubMedCrossRef

Forouzanfar, M., Rabiee, F., Ghaedi, K., Beheshti, S., Tanhaei, S., Shoaraye Nejati, A., et al. (2015). Fndc5 overexpression facilitated neural differentiation of mouse embryonic stem cells. Cell Biology International, 39, 629–637.PubMedCrossRef

Fransen, M., Nordgren, M., Wang, B., & Apanasets, O. (2012). Role of peroxisomes in ROS/RNS-metabolism: Implications for human disease. Biochimica et Biophysica Acta, 1822, 1363–1373.PubMedCrossRef

Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., et al. (2002). alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biology, 4, 160–164.PubMedCrossRef

Ghahrizjani, F. A., Ghaedi, K., Salamian, A., Tanhaei, S., Nejati, A. S., Salehi, H., et al. (2015). Enhanced expression of FNDC5 in human embryonic stem cell-derived neural cells along with relevant embryonic neural tissues. Gene, 557, 123–129.PubMedCrossRef

Giampà, C., Montagna, E., Dato, C., Melone, M. A., Bernardi, G., & Fusco, F. R. (2013). Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington’s disease. PLoS One, 8, e64037.PubMedCentralPubMedCrossRef

Ginsberg, L., Rafique, S., Xuereb, J. H., Rapoport, S. I., & Gershfeld, N. L. (1995). Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer’s disease brain. Brain Research, 698, 223–226.PubMedCrossRef

Goncalves, R. L., Rothschild, D. E., Quinlan, C. L., Scott, G. K., Benz, C. C., & Brand, M. D. (2014). Sources of superoxide/H₂O₂ during mitochondrial proline oxidation. Redox Biology, 2, 901–909.PubMedCentralPubMedCrossRef

Green, D. R., & Kroemer, G. (2004). The pathophysiology of mitochondrial cell death. Science, 305, 626–629.PubMedCrossRef

Greenberg, M. E., Xu, B., Lu, B., & Hempstead, B. L. (2009). New insights in the biology of BDNF synthesis and release: implications in CNS function. Journal of Neuroscience, 29, 12764–12767.PubMedCentralPubMedCrossRef

Guo, C., Sun, L., Chen, X., & Zhang, D. (2013). Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regeneration Research, 8, 2003–2014.PubMedCentralPubMed

Haas, R. H., Parikh, S., Falk, M. J., Saneto, R. P., Wolf, N. I., Darin, N., et al. (2008). The in-depth evaluation of suspected mitochondrial disease. Molecular Genetics and Metabolism, 94, 16–37.PubMedCentralPubMedCrossRef

Han, J.Y., Kim, J.S., Son, J.H. (2014). Mitochondrial homeostasis molecules: regulation by a trio of recessive Parkinson's disease genes. Exp Neurobiol, 23(4), 345–351.PubMedCentralPubMedCrossRef

Handschin, C. (2009). The biology of PGC-1α and its therapeutic potential. Trends in Pharmacological Sciences, 30, 322–329.PubMedCrossRef

Hashemi, M. S., Ghaedi, K., Salamian, A., Karbalaie, K., Emadi-Baygi, M., Tanhaei, S., et al. (2013). Fndc5 knockdown significantly decreased neural differentiation rate of mouse embryonic stem cells. Neuroscience, 231, 296–304.PubMedCrossRef

Herben-Dekker, M., van Oostrom, J. C., Roos, R. A., Jurgens, C. K., Witjes-Ané, M. N., Kremer, H. P., et al. (2014). Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington’s disease. Journal of Neurology, 261, 1387–1397.PubMedCrossRef

Huang, E. J., & Reichardt, L. F. (2001). Neurotrophins: Roles in neuronal development and function. Annual Review of Neuroscience, 24, 677–736.PubMedCentralPubMedCrossRef

Hwang, O. (2013). Role of oxidative stress in Parkinson’s disease. Exp Neurobiol, 22(1), 11–17.PubMedCentralPubMedCrossRef

Ivanov, I.P., Firth, A.E., Michel, A.M., Atkins, J.F., Baranov, P.V. (2011). Identification of evolutionarily conserved non-AUG-initiated N-terminal extensions in human coding sequences. Nucleic Acids Res, 39(10), 4220–4234.PubMedCentralPubMedCrossRef

Ivashchenko, O., Van Veldhoven, P. P., Brees, C., Ho, Y. S., Terlecky, S. R., & Fransen, M. (2011). Intraperoxisomal redox balance in mammalian cells: Oxidative stress and interorganellar cross-talk. Molecular Biology of the Cell, 22, 1440–1451.PubMedCentralPubMedCrossRef

Jin, Y. N., & Johnson, G. V. (2010). The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. Journal of Bioenergetics and Biomembranes, 42, 199–205.PubMedCentralPubMedCrossRef

Johnson, W. T., Johnson, L. A., & Lukaski, H. C. (2005). Serum superoxide dismutase 3 (extracellular superoxide dismutase) activity is a sensitive indicator of Cu status in rats. Journal of Nutritional Biochemistry, 16, 682–692.PubMedCrossRef

Johri, A., & Beal, M. F. (2012). Mitochondrial dysfunction in neurodegenerative diseases. Journal of Pharmacology and Experimental Therapeutics, 342, 619–630.PubMedCentralPubMedCrossRef

Kalmijn, S., Launer, L. J., Ott, A., Witteman, J. C., Hofman, A., & Breteler, M. M. (1997). Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Annals of Neurology, 42, 776–782.PubMedCrossRef

Kassmann, C. M., Lappe-Siefke, C., Baes, M., Brügger, B., Mildner, A., Werner, H. B., et al. (2007). Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nature Genetics, 39, 969–976.PubMedCrossRef

Katsouri, L., Parr, C., Bogdanovic, N., Willem, M., & Sastre, M. (2011). PPARγ co-activator-1α (PGC-1α) reduces amyloid-β generation through a PPARγ-dependent mechanism. Journal of Alzheimer’s Disease, 25, 151–162.PubMed

Kelly, D. P., & Scarpulla, R. C. (2004). Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes and Development, 18, 357–368.PubMedCrossRef

Keogh, M.J., Chinnery, P.F. (2015). Mitochondrial DNA mutations in neurodegeneration. Biochim Biophys Acta, 1847(11), 1401–1411.CrossRef

Kobilo, T., Liu, Q. R., Gandhi, K., Mughal, M., Shaham, Y., & van Praag, H. (2011). Running is the neurogenic and neurotrophic stimulus in environmental enrichment. Learning and Memory, 18, 605–609.PubMedCentralPubMedCrossRef

Koepke, J. I., Nakrieko, K. A., Wood, C. S., Boucher, K. K., Terlecky, L. J., Walton, P. A., & Terlecky, S. R. (2007). Restoration of peroxisomal catalase import in a model of human cellular aging. Traffic, 8, 1590–1600.PubMedCrossRef

Kotiadis, V. N., Duchen, M. R., & Osellame, L. D. (2014). Mitochondrial quality control and communications with the nucleus are important in maintaining mitochondrial function and cell health. Biochimica et Biophysica Acta, 1840, 1254–1265.PubMedCentralPubMedCrossRef

Kou, J., Kovacs, G. G., Höftberger, R., Kulik, W., Brodde, A., Forss-Petter, S., et al. (2011). Peroxisomal alterations in Alzheimer’s disease. Acta Neuropathologica, 122, 271–283.PubMedCentralPubMedCrossRef

Kressler, D., Schreiber, S. N., Knutti, D., & Kralli, A. (2002). The PGC-1-related protein PERC is a selective coactivator of estrogen receptor alpha. Journal of Biological Chemistry, 277, 13918–13925.PubMedCrossRef

Lee, P., Linderman, J. D., Smith, S., Brychta, R. J., Wang, J., Idelson, C., et al. (2014). Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metabolism, 19, 302–309.PubMedCrossRef

Legros, F., Malka, F., Frachon, P., Lombès, A., & Rojo, M. (2004). Organization and dynamics of human mitochondrial DNA. Journal of Cell Science, 117, 2653–2662.PubMedCrossRef

Lezi, E., & Swerdlow, R. H. (2012). Mitochondria in neurodegeneration. Advances in Experimental Medicine and Biology, 942, 269–286.PubMedCentralPubMedCrossRef

Lin, M. T., & Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443, 787–795.PubMedCrossRef

Lin, J., Puigserver, P., Donovan, J., Tarr, P., & Spiegelman, B. M. (2002a). Peroxisome proliferator-activated receptor gamma coactivator 1beta (PGC-1beta), a novel PGC-1-related transcription coactivator associated with host cell factor. Journal of Biological Chemistry, 277, 1645–1648.PubMedCrossRef

Lin, M.Y., & Sheng, Z.H. (2015). Regulation of mitochondrial transport in neurons. Exp Cell Res, 334(1), 35–44.PubMedCrossRef

Lin, J., Wu, P. H., Tarr, P. T., Lindenberg, K. S., St-Pierre, J., Zhang, C. Y., et al. (2004). Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell, 119, 121–135.PubMedCrossRef

Lin, J., Wu, H., Tarr, P. T., Zhang, C. Y., Wu, Z., Boss, O., et al. (2002b). Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature, 418, 797–801.PubMedCrossRef

Lodhi, I. J., & Semenkovich, C. F. (2014). Peroxisomes: A nexus for lipid metabolism and cellular signaling. Cell Metabolism, 19, 380–392.PubMedCentralPubMedCrossRef

Lopez-Huertas, E., Charlton, W. L., Johnson, B., Graham, I. A., & Baker, A. (2000). Stress induces peroxisome biogenesis genes. EMBO Journal, 19, 6770–6777.PubMedCentralPubMedCrossRef

Mailloux, R. J. (2015). Teaching the fundamentals of electron transfer reactions in mitochondria and the production and detection of reactive oxygen species. Redox Biology, 4, 381–398.PubMedCentralPubMedCrossRef

Martin, E., Betuing, S., Pagès, C., Cambon, K., Auregan, G., Deglon, N., et al. (2011). Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington’s disease: role on chromatin remodeling at the PGC-1-alpha promoter. Human Molecular Genetics, 20, 2422–2434.PubMedCentralPubMedCrossRef

Mattson, M. P. (2012). Energy intake and exercise as determinants of brain health and vulnerability to injury and disease. Cell Metabolism, 16, 706–722.PubMedCentralPubMedCrossRef

McAllister, A. K. (2001). Neurotrophins and neuronal differentiation in the central nervous system. Cellular and Molecular Life Sciences, 58, 1054–1060.PubMedCrossRef

McGill, J. K., & Beal, M. F. (2006). PGC-1alpha, a new therapeutic target in Huntington’s disease? Cell, 127, 465–468.PubMedCrossRef

Milnerwood, A. J., & Raymond, L. A. (2010). Early synaptic pathophysiology in neurodegeneration: Insights from Huntington’s disease. Trends in Neurosciences, 33, 513–523.PubMedCrossRef

Mochel, F., & Haller, R. G. (2011). Energy deficit in Huntington disease: Why it matters. Journal of Clinical Investigation, 121, 493–499.PubMedCentralPubMedCrossRef

Momose, Y., Murata, M., Kobayashi, K., Tachikawa, M., Nakabayashi, Y., Kanazawa, I., & Toda, T. (2002). Association studies of multiple candidate genes for Parkinson’s disease using single nucleotide polymorphisms. Annals of Neurology, 51, 133–136.PubMedCrossRef

Monteiro-Junior, R. S., Cevada, T., Oliveira, B. R., Lattari, E., Portugal, E. M., Carvalho, A., & Deslandes, A. C. (2015). We need to move more: Neurobiological hypotheses of physical exercise as a treatment for Parkinson’s disease. Medical Hypotheses,. doi:10.1016/j.mehy.2015.07.011 PubMed

Moon, H. S., Dincer, F., & Mantzoros, C. S. (2013). Pharmacological concentrations of irisin increase cell proliferation without influencing markers of neurite outgrowth and synaptogenesis in mouse H19-7 hippocampal cell lines. Metabolism, 62, 1131–1136.PubMedCentralPubMedCrossRef

Moreira, P. I., Santos, M. S., Seiça, R., & Oliveira, C. R. (2007). Brain mitochondrial dysfunction as a link between Alzheimer’s disease and diabetes. Journal of the Neurological Sciences, 257, 206–214.PubMedCrossRef

Mudò, G., Mäkelä, J., Di Liberto, V., Tselykh, T. V., Olivieri, M., Piepponen, P., et al. (2012). Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease. Cellular and Molecular Life Sciences, 69, 1153–1165.PubMedCrossRef

Murphy, M. P. (2009). How mitochondria produce reactive oxygen species. Biochemical Journal, 417, 1–13.PubMedCentralPubMedCrossRef

Nagley, P., Higgins, G. C., Atkin, J. D., & Beart, P. M. (2010). Multifaceted deaths orchestrated by mitochondria in neurones. Biochimica et Biophysica Acta, 1802, 167–185.PubMedCrossRef

Nicholls, D. G. (2008). Oxidative stress and energy crises in neuronal dysfunction. Annals of the New York Academy of Sciences, 1147, 53–60.PubMedCrossRef

Nixon, R. A., Cataldo, A. M., & Mathews, P. M. (2000). The endosomal–lysosomal system of neurons in Alzheimer’s disease pathogenesis: A review. Neurochemical Research, 25, 1161–1172.PubMedCrossRef

Obulesu, M., & Lakshmi, M. J. (2014). Apoptosis in Alzheimer’s disease: an understanding of the physiology, pathology and therapeutic avenues. Neurochemical Research, 39, 2301–2312.PubMedCrossRef

Ostadsharif, M., Ghaedi, K., Hossein Nasr-Esfahani, M., Mojbafan, M., Tanhaie, S., Karbalaie, K., & Baharvand, H. (2011). The expression of peroxisomal protein transcripts increased by retinoic acid during neural differentiation. Differentiation, 81, 127–132.PubMedCrossRef

Outeiro, T. F., Marques, O., & Kazantsev, A. (2008). Therapeutic role of sirtuins in neurodegenerative disease. Biochimica et Biophysica Acta, 1782, 363–369.PubMedCrossRef

Payne, B. A., & Chinnery, P. F. (2015). Mitochondrial dysfunction in aging: Much progress but many unresolved questions. Biochim Biophys Acta, 1847(11), 1347–1353. CrossRef

Petzold, A., Psotta, L., Brigadski, T., Endres, T., & Lessmann, V. (2015). Chronic BDNF deficiency leads to an age-dependent impairment in spatial learning. Neurobiology of Learning and Memory, 120, 52–60.PubMedCrossRef

Phillips, C., Baktir, M. A., Srivatsan, M., & Salehi, A. (2014). Neuroprotective effects of physical activity on the brain: a closer look at trophic factor signaling. Frontiers in Cellular Neuroscience, 8, 170.PubMedCentralPubMedCrossRef

Picconi, B., Piccoli, G., & Calabresi, P. (2012). Synaptic dysfunction in Parkinson’s disease. Advances in Experimental Medicine and Biology, 970, 553–572.PubMedCrossRef

Picone, P., Nuzzo, D., Caruana, L., Scafidi, V., Di Carlo, M. (2014). Mitochondrial dysfunction: different routes to Alzheimer's disease therapy. Oxid Med Cell Longev, 2014, 780179.PubMedCentralPubMedCrossRef

Pizzorusso, T., Ratto, G. M., Putignano, E., & Maffei, L. (2000). Brain-derived neurotrophic factor causes cAMP response element-binding protein phosphorylation in absence of calcium increases in slices and cultured neurons from rat visual cortex. Journal of Neuroscience, 20, 2809–2816.PubMed

Przedborski, S., Vila, M., & Jackson-Lewis, V. (2003). Neurodegeneration: What is it and where are we? Journal of Clinical Investigation, 111, 3–10.PubMedCentralPubMedCrossRef

Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., & Spiegelman, B. M. (1998). A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell, 92, 829–839.PubMedCrossRef

Qin, W., Haroutunian, V., Katsel, P., Cardozo, C. P., Ho, L., Buxbaum, J. D., & Pasinetti, G. M. (2009). PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Archives of Neurology, 66, 352–361.PubMedCentralPubMedCrossRef

Qin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., Chen, L., et al. (2006). Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. Journal of Biological Chemistry, 281, 21745–21754.PubMedCrossRef

Rabiee, F., Forouzanfar, M., Ghazvini Zadegan, F., Tanhaei, S., Ghaedi, K., Motovali Bashi, M., et al. (2014). Induced expression of Fndc5 significantly increased cardiomyocyte differentiation rate of mouse embryonic stem cells. Gene, 551, 127–137.PubMedCrossRef

Radak, Z., Chung, H. Y., & Goto, S. (2005). Exercise and hormesis: Oxidative stress-related adaptation for successful aging. Biogerontology, 6, 71–75.PubMedCrossRef

Raschke, S., Elsen, M., Gassenhuber, H., Sommerfeld, M., Schwahn, U., Brockmann, B., et al. (2013). Evidence against a beneficial effect of irisin in humans. PLoS ONE, 8, e73680.PubMedCentralPubMedCrossRef

Reddy, P. H. (2009). Role of mitochondria in neurodegenerative diseases: Mitochondria as a therapeutic target in Alzheimer’s disease. CNS Spectrums, 14, 8–13. discussion 16–18.PubMedCentralPubMed

Reichardt, L. F. (2006). Neurotrophin-regulated signalling pathways. Philosophical Transactions of the Royal Society of London. Series B, Biological sciences, 361, 1545–1564.PubMedCentralPubMedCrossRef

Rinnerthaler, M., Bischof, J., Streubel, M. K., Trost, A., & Richter, K. (2015). Oxidative stress in aging human skin. Biomolecules, 5, 545–589.PubMedCentralPubMedCrossRef

Rossignol, D. A., & Frye, R. E. (2012). A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Molecular Psychiatry, 17, 389–401.PubMedCentralPubMedCrossRef

Ruetenik, A., & Barrientos, A. (2015) Dietary restriction, mitochondrial function and aging: From yeast to humans. Biochim Biophys Acta, 1847(11), 1434–1447.PubMedCrossRef

Santos, M. J., Quintanilla, R. A., Toro, A., Grandy, R., Dinamarca, M. C., Godoy, J. A., & Inestrosa, N. C. (2005). Peroxisomal proliferation protects from beta-amyloid neurodegeneration. Journal of Biological Chemistry, 280, 41057–41068.PubMedCrossRef

Scarpulla, R. C. (2008). Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiological Reviews, 88, 611–638.PubMedCrossRef

Schäbitz, W. R., Sommer, C., Zoder, W., Kiessling, M., Schwaninger, M., & Schwab, S. (2000). Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke, 31, 2212–2217.PubMedCrossRef

Schon, E. A., DiMauro, S., Hirano, M., & Gilkerson, R. W. (2010). Therapeutic prospects for mitochondrial disease. Trends in Molecular Medicine, 16, 268–276.PubMedCentralPubMedCrossRef

Schreiber, S. N., Emter, R., Hock, M. B., Knutti, D., Cardenas, J., Podvinec, M., et al. (2004). The estrogen-related receptor alpha (ERRalpha) functions in PPARgamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis. Proceedings of the National Academy of Sciences USA, 101, 6472–6477.CrossRef

Selkoe, D. J., & Schenk, D. (2003). Alzheimer’s disease: Molecular understanding predicts amyloid-based therapeutics. Annual Review of Pharmacology and Toxicology, 43, 545–584.PubMedCrossRef

Sen, S., Nesse, R. M., Stoltenberg, S. F., Li, S., Gleiberman, L., Chakravarti, A., et al. (2003). A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology, 28, 397–401.PubMedCrossRef

Sharon, R., Bar-Joseph, I., Frosch, M. P., Walsh, D. M., Hamilton, J. A., & Selkoe, D. J. (2003a). The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson’s disease. Neuron, 37, 583–595.PubMedCrossRef

Sharon, R., Bar-Joseph, I., Mirick, G. E., Serhan, C. N., & Selkoe, D. J. (2003b). Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. Journal of Biological Chemistry, 278, 49874–49881.PubMedCrossRef

Sheikh, F. G., Pahan, K., Khan, M., Barbosa, E., & Singh, I. (1998). Abnormality in catalase import into peroxisomes leads to severe neurological disorder. Proceedings of the National Academy of Sciences, 95, 2961–2966.CrossRef

Sheng, B., Wang, X., Su, B., Lee, H. G., Casadesus, G., Perry, G., & Zhu, X. (2012). Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer’s disease. Journal of Neurochemistry, 120, 419–429.PubMedCentralPubMedCrossRef

Shin, J. H., Ko, H. S., Kang, H., Lee, Y., Lee, Y. I., Pletinkova, O., et al. (2011). PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson’s disease. Cell, 144, 689–702.PubMedCentralPubMedCrossRef

Shutt, T.E.,& McBride, H.M. (2013). Staying cool in difficult times: mitochondrial dynamics, quality control and the stress response. Biochim Biophys Acta, 1833(2), 417–424.PubMedCrossRef

Song, W., Chen, J., Petrilli, A., Liot, G., Klinglmayr, E., Zhou, Y., et al. (2011). Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nature Medicine, 17, 377–382.PubMedCentralPubMedCrossRef

Spiegelman, B. M. (2013). Banting Lecture 2012 Regulation of adipogenesis: Toward new therapeutics for metabolic disease. Diabetes, 62, 1774–1782.PubMedCentralPubMedCrossRef

Steinberg, S. J., Dodt, G., Raymond, G. V., Braverman, N. E., Moser, A. B., & Moser, H. W. (2006). Peroxisome biogenesis disorders. Biochimica et Biophysica Acta, 1763, 1733–1748.PubMedCrossRef

St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jäger, S., et al. (2006). Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell, 127, 397–408.PubMedCrossRef

Sun, M., Kong, L., Wang, X., Lu, X. G., Gao, Q., & Geller, A. I. (2005). Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson’s disease. Brain Research, 1052, 119–129.PubMedCentralPubMedCrossRef

Tapia-Arancibia, L., Aliaga, E., Silhol, M., & Arancibia, S. (2008). New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Research Reviews, 59, 201–220.PubMedCrossRef

Tapia-Arancibia, L., Rage, F., Givalois, L., & Arancibia, S. (2004). Physiology of BDNF: Focus on hypothalamic function. Frontiers in Neuroendocrinology, 25, 77–107.PubMedCrossRef

Tillement, L., Lecanu, L., & Papadopoulos, V. (2011). Alzheimer’s disease: Effects of β-amyloid on mitochondria. Mitochondrion, 11, 13–21.PubMedCrossRef

Tong, L., Balazs, R., Thornton, P. L., & Cotman, C. W. (2004). Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. Journal of Neuroscience, 24, 6799–6809.PubMedCrossRef

Trempe, J.F., & Fon, E.A. (2013). Structure and Function of Parkin, PINK1, and DJ-1, the Three Musketeers of Neuroprotection. Front Neurol, 4, 38.PubMedCentralPubMedCrossRef

Tretter, L., Sipos, I., & Adam-Vizi, V. (2004). Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson’s disease. Neurochemical Research, 29, 569–577.PubMedCrossRef

Tsai, S. J. (2006). TrkB partial agonists: potential treatment strategy for epilepsy, mania, and autism. Medical Hypotheses, 66, 173–175.PubMedCrossRef

Tsunemi, T., Ashe, T. D., Morrison, B. E., Soriano, K. R., Au, J., Roque, R. A., et al. (2012). PGC-1α rescues Huntington’s disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Science Translational Medicine, 4, 142ra197.CrossRef

van der Valk, P., Gille, J. J., Oostra, A. B., Roubos, E. W., Sminia, T., & Joenje, H. (1985). Characterization of an oxygen-tolerant cell line derived from Chinese hamster ovary. Antioxygenic enzyme levels and ultrastructural morphometry of peroxisomes and mitochondria. Cell and Tissue Research, 239, 61–68.PubMedCrossRef

Vega, R. B., Huss, J. M., & Kelly, D. P. (2000). The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Molecular and Cellular Biology, 20, 1868–1876.PubMedCentralPubMedCrossRef

Ventriglia, M., Bocchio Chiavetto, L., Benussi, L., Binetti, G., Zanetti, O., Riva, M. A., & Gennarelli, M. (2002). Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer’s disease. Molecular Psychiatry, 7, 136–137.PubMedCrossRef

Vila, M., & Przedborski, S. (2003). Targeting programmed cell death in neurodegenerative diseases. Nature Reviews Neuroscience, 4, 365–375.PubMedCrossRef

Villena, J. A. (2015). New insights into PGC-1 coactivators: redefining their role in the regulation of mitochondrial function and beyond. FEBS Journal, 282, 647–672.PubMedCrossRef

Volakakis, N., Kadkhodaei, B., Joodmardi, E., Wallis, K., Panman, L., Silvaggi, J., et al. (2010). NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection. Proceedings of the National Academy of Sciences USA, 107, 12317–12322.CrossRef

Wallace, D. C., & Fan, W. (2009). The pathophysiology of mitochondrial disease as modeled in the mouse. Genes and Development, 23, 1714–1736.PubMedCentralPubMedCrossRef

Wanders, R. J., & Waterham, H. R. (2005). Peroxisomal disorders I: Biochemistry and genetics of peroxisome biogenesis disorders. Clinical Genetics, 67, 107–133.PubMedCrossRef

Wanders, R. J., & Waterham, H. R. (2006). Peroxisomal disorders: The single peroxisomal enzyme deficiencies. Biochimica et Biophysica Acta, 1763, 1707–1720.PubMedCrossRef

Wang, R., Li, J. J., Diao, S., Kwak, Y. D., Liu, L., Zhi, L., et al. (2013). Metabolic stress modulates Alzheimer’s β-secretase gene transcription via SIRT1-PPARγ-PGC-1 in neurons. Cell Metabolism, 17, 685–694.PubMedCrossRef

Wenz, T. (2009). PGC-1alpha activation as a therapeutic approach in mitochondrial disease. IUBMB Life, 61, 1051–1062.PubMedCrossRef

Wenz, T. (2011). Mitochondria and PGC-1α in aging and age-associated diseases. Journal of Aging Research, 2011, 810619.PubMedCentralPubMedCrossRef

West, A. P., Shadel, G. S., & Ghosh, S. (2011). Mitochondria in innate immune responses. Nature Reviews Immunology, 11, 389–402.PubMedCentralPubMedCrossRef

Weydt, P., Soyal, S. M., Gellera, C., Didonato, S., Weidinger, C., Oberkofler, H., et al. (2009). The gene coding for PGC-1alpha modifies age at onset in Huntington’s Disease. Molecular neurodegeneration, 4, 3.PubMedCentralPubMedCrossRef

Winterbourn, C. C. (1995). Toxicity of iron and hydrogen peroxide: The Fenton reaction. Toxicology Letters, 82–83, 969–974.PubMedCrossRef

Witte, M. E., Geurts, J. J., de Vries, H. E., van der Valk, P., & van Horssen, J. (2010). Mitochondrial dysfunction: A potential link between neuroinflammation and neurodegeneration? Mitochondrion, 10, 411–418.PubMedCrossRef

Wood, C. S., Koepke, J. I., Teng, H., Boucher, K. K., Katz, S., Chang, P., et al. (2006). Hypocatalasemic fibroblasts accumulate hydrogen peroxide and display age-associated pathologies. Traffic, 7, 97–107.PubMedCrossRef

Wrann, C. D., White, J. P., Salogiannnis, J., Laznik-Bogoslavski, D., Wu, J., Ma, D., et al. (2013). Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metabolism, 18, 649–659.PubMedCentralPubMedCrossRef

Wu, Z., Huang, X., Feng, Y., Handschin, C., Gullicksen, P. S., Bare, O., et al. (2006). Transducer of regulated CREB-binding proteins (TORCs) induce PGC-1alpha transcription and mitochondrial biogenesis in muscle cells. Proceedings of the National Academy of Sciences USA, 103, 14379–14384.CrossRef

Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., et al. (1999). Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell, 98, 115–124.PubMedCrossRef

Yakunin, E., Moser, A., Loeb, V., Saada, A., Faust, P., Crane, D. I., et al. (2010). alpha-Synuclein abnormalities in mouse models of peroxisome biogenesis disorders. Journal of Neuroscience Research, 88, 866–876.PubMedCentralPubMed

Yang, L., Long, Q., Liu, J., Tang, H., Li, Y., Bao, F., Qin, D., Pei, D., Liu, X. (2015). Mitochondrial fusion provides an ‘initial metabolic complementation’ controlled by mtDNA. Cell Mol Life Sci, 72(13):2585-2598. PubMedCrossRef

Yu, S. P. (2003). Na(+), K(+)-ATPase: the new face of an old player in pathogenesis and apoptotic/hybrid cell death. Biochemical Pharmacology, 66, 1601–1609.PubMedCrossRef

Zhang, Y., Ma, K., Song, S., Elam, M. B., Cook, G. A., & Park, E. A. (2004). Peroxisomal proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1 alpha) enhances the thyroid hormone induction of carnitine palmitoyltransferase I (CPT-I alpha). Journal of Biological Chemistry, 279, 53963–53971.PubMedCrossRef

Zhao, W., Varghese, M., Yemul, S., Pan, Y., Cheng, A., Marano, P., et al. (2011). Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-1α) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis. Molecular Neurodegeneration, 6, 51.PubMedCentralPubMedCrossRef

Zheng, B., Liao, Z., Locascio, J. J., Lesniak, K. A., Roderick, S. S., Watt, M. L., et al. (2010). PGC-1α, a potential therapeutic target for early intervention in Parkinson’s disease. Science Translational Medicine, 2, 52ra73.PubMedCentralPubMedCrossRef

Zorzano, A., & Claret, M. (2015). Implications of mitochondrial dynamics on neurodegeneration and on hypothalamic dysfunction. Front Aging Neurosci, 7, 101.PubMedCentralPubMedCrossRef

Titel: Does PGC1α/FNDC5/BDNF Elicit the Beneficial Effects of Exercise on Neurodegenerative Disorders?
verfasst von: Mohammad Jodeiri Farshbaf
Kamran Ghaedi
Timothy L. Megraw
Jennifer Curtiss
Mahsa Shirani Faradonbeh
Pooneh Vaziri
Mohammad Hossein Nasr-Esfahani
Publikationsdatum: 01.03.2016
Verlag: Springer US
Erschienen in: NeuroMolecular Medicine / Ausgabe 1/2016
Print ISSN: 1535-1084
Elektronische ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-015-8370-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

ApoA1, ApoJ and ApoE Plasma Levels and Genotype Frequencies in Cerebral Amyloid Angiopathy

Vorinostat Modulates the Imbalance of T Cell Subsets, Suppresses Macrophage Activity, and Ameliorates Experimental Autoimmune Uveoretinitis

Proteomic Profiling in the Brain of CLN1 Disease Model Reveals Affected Functional Modules

Astrocyte-Dependent Vulnerability to Excitotoxicity in Spermine Oxidase-Overexpressing Mouse

The Variant p.(Arg183Trp) in SPTLC2 Causes Late-Onset Hereditary Sensory Neuropathy